Clinical Trial Update: Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of Tarlatamab in patients with advanced extrapulmonary neuroendocrine carcinomas, including pancreatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma of the Pancreas
• Neuroendocrine Carcinoma of the Prostate

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Inkeun Park | Conditions: Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas | Phase 2 | Status: RECRUITING